Synthetic Biologics, Inc. (SYN): history, ownership, mission, how it works & makes money

From its 1986 start as Sheffield Pharmaceuticals through a 2006 reverse merger, a 2008 rebrand and its 2012 reincorporation as Synthetic Biologics before becoming Theriva Biologics in 2022, this microbe-focused biotech-now trading on the NYSE American under TOVX-is capturing attention with a clinical-stage pipeline that includes lead programs SYN-010 and SYN-004 (ribaxamase) aimed at preserving the gut microbiome to address IBS-C, C. difficile and antibiotic-associated complications; the stock last traded at 0.1964 USD (down -0.02 USD (-0.10%)) with an opening price of 0.22 USD, an intraday high of 0.22 and low of 0.1947 on volume of 2,670,323 shares (latest trade Monday, December 15, 17:15:00 PST), while the company-employing 22 people as of March 6, 2025-funds R&D through public offerings, private placements, licensing deals, milestone payments and collaborations as it advances microbiome-preserving therapeutics through clinical trials.

Synthetic Biologics, Inc. (SYN): Intro

• Ticker / Market: SYN - U.S. equity
• Primary focus: microbiome-targeted therapeutics and biologics
• Headquarters & corporate structure: publicly traded U.S. corporation

History & Strategic Evolution

• Origins: Founded to commercialize microbiome- and biologic-based approaches to reduce disease burden from antibiotic-associated conditions and other indications.
• Pipeline evolution: Over time, programs have shifted between clinical-stage therapeutics, platform development, and partnering/licensing strategies depending on clinical outcomes and capital access.
• Corporate actions: The company has historically supplemented R&D through financing rounds, strategic collaborations, and asset licensing to extend runway and unlock program value.

Ownership & Governance

• Shareholder base: A mix of retail investors, institutional holders, and insiders typical for small-cap biotech listings (detailed holdings change frequently via SEC filings).
• Board and management: Comprised of industry-experienced executives and directors focused on clinical development, regulatory strategy, and capital markets navigation.

Mission & Strategic Objectives

• Core mission: Develop targeted biologic and microbiome-based therapeutics that reduce incidence/severity of infectious and gastrointestinal disorders.
• Strategic objectives: Advance prioritized clinical programs, seek partnerships/licensing for non-core assets, and manage capital to sustain clinical milestones.

How the Science & Business Model Work

• Scientific approach: Therapeutics aimed at modifying microbial communities, neutralizing toxins, or preventing pathogen overgrowth while sparing beneficial flora.
• Preclinical/clinical pathway: Discovery → IND-enabling studies → phase 1-3 clinical trials → regulatory approval or strategic out-licensing.
• Commercial strategy options: Direct commercialization for niche indications, partnering for large-market launches, and licensing to larger pharma for late-stage assets.

How Synthetic Biologics, Inc. (SYN) Makes Money

• License & collaboration revenue: Upfronts, milestones, and royalties from partnered programs or out-licensed assets.
• Grants & non-dilutive funding: Government or foundation grants supporting preclinical/clinical work where applicable.
• Equity financing: Sale of common stock, private placements, or public offerings to raise operating capital-typical for clinical-stage biotechs.
• Milestone & royalty streams: Contingent on successful development and commercialization by SYN or partners.

Key Operational & Financial Considerations

• Cash burn and financing need: Clinical development is capital-intensive; ongoing financing or partnerships are common levers to extend runway.
• Clinical risk: Value drivers are tied to clinical readouts and regulatory progress; binary events can drive significant stock volatility.
• Market liquidity: Current intraday volume (2,670,323) and sub-dollar share price indicate active trading but potential volatility and spread considerations for large orders.

Synthetic Biologics, Inc. (SYN): History

• Incorporated 1986 as Sheffield Pharmaceuticals, Inc., initial focus on pharmaceutical products.
• 2006: Reverse merger with Pipex Therapeutics, Inc. (Delaware, formed 2001); name changed to Pipex Pharmaceuticals, Inc.
• October 2008: Rebranded to Adeona Pharmaceuticals, Inc., signaling new strategic direction.
• February 15, 2012: Reincorporated in Nevada and renamed Synthetic Biologics, Inc.
• October 12, 2022: Name changed to Theriva Biologics, Inc., emphasizing therapeutics to preserve the microbiome.
• As of March 6, 2025: Employed 22 people, with a significant portion on research and clinical development teams in the U.S. and Spain.

• Ownership structure: historically public company with shareholders; post-name-change corporate governance maintained board and executive leadership consistent with small-cap biopharma (majority institutional and retail shareholders typical for firms of this size).
• Mission focus: develop therapeutics designed to preserve the microbiome to protect and restore patient health - see Mission Statement, Vision, & Core Values (2026) of Synthetic Biologics, Inc.
• How it works / revenue model:
  • R&D-driven - value creation through discovery, preclinical and clinical milestones.
  • Potential revenue streams: licensing deals, milestone and royalty payments from partners, co-development collaborations, and eventual product sales if candidates gain regulatory approval.
  • Capital strategy: typical for small biotech - equity raises (public offerings/PIPEs), partner upfront/milestone payments, and non-dilutive grants when available.

Synthetic Biologics, Inc. (SYN): Ownership Structure

• Corporate name history: Sheffield Pharmaceuticals, Inc.; Pipex Pharmaceuticals, Inc.; Adeona Pharmaceuticals, Inc.; Synthetic Biologics, Inc.
• Public listing and ticker: traded publicly (historical listings); current investor materials reference Synthetic Biologics, Inc. (SYN).
• Workforce: 22 employees as of March 6, 2025, with R&D and clinical teams primarily in the United States and Spain.
• Shareholder composition: mix of institutional investors, individual shareholders and company insiders.
• Financing: combination of public offerings and private placements used to fund R&D and clinical development.

• Insider and institutional holdings: meaningful insider stakes alongside institutional positions-ownership percentages vary with each financing event and market trading.
• Use of proceeds from financings: primarily to support research, clinical trials and related development activities.

Synthetic Biologics, Inc. (SYN): Mission and Values

• Mission: Preserve the microbiome to protect and restore patient health.
• Core values: innovation, scientific excellence, patient-centric R&D, and collaborative partnerships.
• Strategic focus: advance a pipeline of therapeutics through well-controlled clinical trials and academic/industry collaborations.

• SYN-010 - intended to reduce the functional impact of methane-producing organisms in the gut to treat an underlying cause of IBS with constipation (IBS‑C).
• SYN-004 (ribaxamase) - an orally administered beta-lactamase designed to degrade certain IV beta‑lactam antibiotics in the GI tract to protect the microbiome and reduce risks of C. difficile infection (CDI), antibiotic‑associated diarrhea (AAD), and limit antimicrobial resistance (AMR) emergence.
• Preclinical/early research - monoclonal antibody candidates aimed at preventing and treating pertussis; discovery-stage biologics for phenylketonuria (PKU).

• Clinical development pathway: move lead programs through randomized controlled trials with defined microbiome and clinical endpoints to create value for licensing or commercialization.
• Collaborations & licensing: pursue partnerships with academic institutions, biotech and pharma to accelerate development and expand commercial opportunities.
• Commercial pathways: for microbiome-protecting products (e.g., ribaxamase), target hospital and inpatient antibiotic settings where CDI and AAD risk is highest; for IBS‑C therapies, target gastroenterology specialty markets.
• Non-dilutive funding & strategic transactions: utilize grants, collaborations, licensing milestones and potential asset sales to extend runway while advancing clinical programs.

• Rigorous clinical testing with microbiome-aware endpoints to demonstrate both clinical benefit and preservation of microbial ecology.
• Patient-centric trial designs and safety monitoring focused on vulnerable inpatient populations (antibiotic recipients) and chronic GI patients (IBS‑C).
• Collaboration with academic centers and industry partners to access specialized expertise in microbiome science, immunology and clinical gastroenterology.

Synthetic Biologics, Inc. (SYN): How It Works

• Core approach: protect or modulate the gut microbiome to prevent dysbiosis and downstream disease-using orally delivered agents that act locally in the GI tract.
• Lead assets: SYN-010 and SYN-004 (ribaxamase) are designed to modulate or protect the gut microbiome to prevent/mitigate specific conditions associated with antibiotic exposure and GI dysfunction.
• Development model: clinical-stage progression across Phase 1-3 trials with safety, pharmacokinetics, microbiome, and clinical efficacy endpoints.

• Microbiome preservation technology: oral formulations that act in the intestinal lumen to neutralize deleterious exposures or shift microbial composition without systemic absorption.
• SYN-004 (ribaxamase): an orally administered β-lactamase enzyme intended to degrade certain IV β-lactam antibiotics excreted into the gut, reducing antibiotic-driven dysbiosis and subsequent risks of C. difficile infection and other complications.
• SYN-010: formulated to modulate gut microbial metabolites (e.g., short-chain fatty acids) and host-microbe interactions to address functional GI disorders and antibiotic-associated complications.
• Delivery and safety: designed for minimal systemic exposure, focusing action in the gut to reduce systemic safety concerns and preserve systemic antibiotic efficacy.

• Trial progression: staggered Phase 1 safety and PK studies, Phase 2 proof-of-concept trials measuring microbiome endpoints and clinical outcomes, and larger Phase 3 registrational studies when warranted.
• Endpoints and biomarkers: microbial diversity (alpha/beta diversity), pathogen colonization rates, incidence of antibiotic-associated diarrhea/C. difficile, patient-reported outcomes for GI symptoms, and safety/tolerability profiles.
• Academic and CRO collaborations: partnerships with university microbiome centers and contract research organizations for sequencing, bioinformatics, and trial execution to accelerate development and validate translational science.
• Quality & regulatory alignment: GMP manufacturing for oral biologics/enzymes, GLP tox studies as required, and close interaction with regulatory agencies to align on endpoints, trial design, and data packages for approval pathways.

• Clinical-stage value creation: increasing asset value through successful trial readouts, enabling licensing, strategic partnerships, or acquisition by larger biopharma.
• Licensing & collaborations: non-dilutive revenue via licensing of programs, co-development agreements, or milestone and royalty streams from partnered commercialization.
• Grant and research funding: targeted grants or sponsored research from academic/industry partners to support specific translational studies.
• Capital markets: equity raises (registered offerings, private placements) and occasional debt to fund continued R&D and operations until commercial revenue streams are established.

• Academic collaborations: sequence-based microbiome characterization, mechanistic studies, and translational biomarker development with university labs and clinical research centers.
• Contract partners: GMP manufacturers for oral enzyme formulations, CROs for trial conduct, and specialty labs for microbiome sequencing and bioinformatics.
• Out-licensing potential: programs with strong safety and microbiome-protective data are positioned for partnering with larger pharma focused on anti-infectives, gastroenterology, or critical care.

Synthetic Biologics, Inc. (SYN): How It Makes Money

• Licensing & Partnerships - SYN licenses technology and enter collaborations with pharmaceutical and biotechnology companies, structuring deals that can include upfront fees, research funding, milestone payments as candidates progress through clinical development, and downstream royalties on sales.
• Collaborations with Academia & Research Organizations - SYN participates in cooperative research agreements and resource-sharing collaborations that can include sponsored research payments or shared IP arrangements.
• Milestones & Royalties - As partnered candidates hit development or regulatory milestones, SYN may receive contractual milestone payments; successful commercialization by a partner would typically trigger royalty streams.
• Grants & Government Contracts - SYN pursues government and nonprofit grants or contracts that provide non-dilutive funding for specific research programs.
• Capital Markets Activity - The company augments operational funding through public offerings, registered direct offerings and private placements to finance ongoing R&D and trials.